<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026441</url>
  </required_header>
  <id_info>
    <org_study_id>Vela100</org_study_id>
    <nct_id>NCT01026441</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Safety and Efficacy of the Vela100</brief_title>
  <official_title>Clinical Study to Evaluate the Safety and Efficacy of the Vela100/eShape Uno Device for Cellulite and Circumference Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneron Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syneron Medical</source>
  <brief_summary>
    <textblock>
      This study is intended to test the safety of the Vela100 device when used for treatment for
      cellulite and circumference temporary reduction.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Product was not developed and study was cancelled
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>End of treatment, at 1 month FU</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cellulite Reduction</condition>
  <condition>Circumference Reduction</condition>
  <arm_group>
    <arm_group_label>Treatment for cellulite and circumference reduction</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will be treated with the device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vela100 (Aesthetic)</intervention_name>
    <description>6 treatments once a week</description>
    <arm_group_label>Treatment for cellulite and circumference reduction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent agreement signed by the subject.

          -  Healthy males or females older than 21 years of age but not older than 60 years of
             age.

          -  Fitzpatrick Skin Type I to VI

          -  Having at least two areas (abdomen, buttocks and thighs) suitable for treatment.

          -  BMI score is greater than 18.5 and less than 29.9 - normal to overweight, but not
             obese.

          -  Willingness to follow the treatment and follow-up schedule and the post-treatment
             care.

          -  Willingness to refrain from a change in diet/drinking/exercise/medication regimen for
             the entire course of the study.

          -  For female of child bearing potential - using a medically acceptable form of birth
             control at least 3 months prior to enrollment and during the entire course of the
             study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with
             spermicide, or abstinence).

        Exclusion Criteria:

          -  Pregnant or planning to become pregnant, having given birth (vaginal birth or
             Caesarean surgery) less than 9 months ago, and/or breastfeeding.

          -  Having any active electrical implant anywhere in the body, such as a pacemaker or an
             internal defibrillator.

          -  Having a permanent implant in the treated areas, such as metal plates and screws or an
             injected chemical substance.

          -  Having received treatment with laser, RF or other devices in the treated areas within
             6 months of treatment or during the study.

          -  Having undergone a liposuction surgery or any contouring treatment in the areas
             intended for treatment within 9 months of treatment or during the study.

          -  For post-liposuction areas, the procedure should also not have been performed more
             than 2 years prior to this study.

          -  Having undergone any other surgery in the treated areas within 9 months of treatment
             or during the study.

          -  Having or undergoing any form of treatment for active cancer, or having a history of
             skin cancer or any other cancer in the areas to be treated, including presence of
             malignant or pre-malignant pigmented lesions.

          -  Suffering from significant concurrent illness, such as cardiac disorders, diabetes
             (type I or II), lupus, porphyria, or pertinent neurological disorders.

          -  Having a known anticoagulative or thromboembolic condition or taking anticoagulation
             medications one week prior to and during the treatment course (to allow inclusion,
             temporary cessation of use as per the subject's physician discretion).

          -  History of immunosuppression/immune deficiency disorders (including HIV infection or
             AIDS) or currently using immunosuppressive medications.

          -  Suffering from hormonal imbalance which may affect weight or cellulite, as per the
             Investigator's discretion.

          -  History of significant lymphatic drainage problems. Suffering from significant skin
             conditions in the treated areas or inflammatory skin conditions, including, but not
             limited to, open lacerations or abrasions and active cold sores or herpes sores prior
             to treatment (duration of resolution as per the Investigator's discretion) or during
             the treatment course.

          -  History of keloid scarring or of abnormal wound healing.

          -  History of being especially prone to bruising.

          -  History of epidermal or dermal disorders (particularly if involving collagen or
             microvascularity).

          -  Use of isotretinoin (AccutaneÂ®) within 6 months of treatment or during the study.

          -  Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing
             agents) during, as well as two weeks before and after, the treatment course.

          -  Use of anti-cellulite creams within a month of treatment or during the course of the
             study.

          -  If any allergy that is related to the lotion used in this study appears, subjects may
             be excluded from the study.

          -  Recently tanned in areas to be treated and/or unable or unlikely to refrain from
             tanning during the study.

          -  Significant change in diet or exercise regimen within a month of enrollment or during
             this study and/or weight loss or gain of 10 lbs (4.5 kgs) within 2 months of
             enrollment or during this study.

          -  Participation in a study of another device or drug within 1 month prior to enrollment
             or during this study.

          -  As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orange Coast Women's Medical Group</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kavali Plastic Surgery and Skin Renewal Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>VP Research and Development</name_title>
    <organization>Syneron</organization>
  </responsible_party>
  <keyword>Aesthetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

